APUS 10-Q filed 2026-11-16 | Key takeaways
APUS filed its 10-Q; the most relevant disclosure change is expanded Discontinued operations and deconsolidation: Lokahi Therapeutics Inc. was deconsolidated on July 14, 2026 upon merger with Glucotrack, Inc.; company received 37,884 Glucotrack common shares and rights to 2,269,100 Series A preferred shares (as converted), measured at $962,935 total fair value; gain on de. Customer concentration: Two customers (Customer A and Customer B) represented 100% of revenue; Two customers represented 100% of accounts_rec...
Key takeaways
Digital assets: Company holds $142.4 million in digital assets (93% of total assets), consisting of Bitcoin ($92.7 million, 65%), NILA tokens ($49.7 million, 35%), with Bitcoin price rising from $58,416 at June 30 to $83,780 at September 30.
Discontinued BioBusiness: Lokahi deconsolidated July 14, 2026 upon merger with Glucotrack; company received 37,884 Glucotrack common shares and rights to 2.3 million Series A preferred shares, recorded at $252,230 fair value after $710,705 Q3 loss.
Convertible note: $425,000 of principal converted to 305,002 shares at $1.3934 per share in September 2026; remaining principal of $10.5 million matures December 8, 2026 with forbearance expired June 30, 2026.
Going concern: Cash of only $17,912 as of September 30, 2026; substantial doubt exists about ability to continue as going concern within one year of filing date.
Customer concentration: Two customers account for 100% of Q3 and nine-month 2026 revenue and all accounts receivable ($2.48 million).
Key metrics
Customer concentration
Disclosure changes
- Discontinued operations and deconsolidation
Lokahi Therapeutics Inc. was deconsolidated on July 14, 2026 upon merger with Glucotrack, Inc.; company received 37,884 Glucotrack common shares and rights to 2,269,100 Series A preferred shares (as converted), measured at $962,935 total fair value; gain on deconsolidation of $7,803,653 recognized in discontinued operations.
Strategic shift away from biopharmaceutical operations to digital asset focus; BioBusiness results now presented as discontinued operations for all periods. - Segment reporting
Company now operates in one reportable segment (Digital Asset) following disposal of BioBusiness; prior periods restated to show BioBusiness as discontinued operations.
Company's operations now entirely focused on digital asset holding, trading, and blockchain technology services. - Revenue recognition
First reported revenue from continuing operations: $2.48 million from software development services to two customers, recognized at point in time upon delivery; also $418,899 digital asset yield income from managed bitcoin yield strategy.
Company generating operating revenue for first time as Digital Asset segment entity. - Digital asset yield income presentation
Digital asset yield income reclassified from other income to revenue beginning Q3 2026; $282,732 for Q2 2026 reclassified; effective April 1, 2026, TechyTrade appointed Calfin Capital as discretionary investment manager for portion of bitcoin holdings.
Change in financial statement presentation to reflect yield generation as principal ongoing activity. - Investment in equity securities
Investment in Glucotrack of $252,230 as of September 30, 2026, comprising 37,884 common shares ($4,142) and Series A preferred stock rights ($248,088 on as-converted basis), measured at fair value with $710,705 Q3 loss recognized.
New investment received in exchange for company's 49% interest in Lokahi; subject to Glucotrack stock price volatility. - Related party transactions
New related-party agreements: September 2026, MindWave entered 12-month software development agreement with AQUAE Holdings Pte. Ltd. for $1.112 million plus 20% of ALCI credits; August 2026, FreeT assigned Apitox royalty and revenue participation rights to company with no monetary consideration.
Company expanding blockchain services with related parties; Apitox rights provide potential future royalty stream.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow APUS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.